Spinogenix Secures WHO Approval for Fragile X Therapy Name
Event summary
- WHO approved 'codabakalner' as the INN for Spinogenix's SPG601 therapy.
- Codabakalner is a first-in-class oral treatment for Fragile X Syndrome (FXS).
- Spinogenix plans to initiate CLARITY Phase 2b/3 trial for codabakalner.
- Therapy has received Orphan Drug and Fast Track designations from FDA and EMA.
The big picture
Spinogenix's WHO approval for codabakalner underscores the growing focus on synaptic dysfunction in neurodevelopmental disorders. The company is part of a broader trend toward precision therapies targeting specific genetic causes of conditions like FXS, which has seen limited treatment options until now. Success here could validate Spinogenix's platform approach to synaptic regeneration across multiple neurological diseases.
What we're watching
- Clinical Trial Progress
- The pace at which Spinogenix advances the CLARITY Phase 2b/3 trial will determine codabakalner's path to market.
- Regulatory Momentum
- Whether Spinogenix can maintain regulatory support through FDA and EMA for both FXS and ALS indications.
- Therapeutic Differentiation
- How codabakalner's mechanism of positively modulating BK channels will position it against emerging Fragile X treatments.
Related topics